OppenheimerFunds’s Haemonetics HAE Stock Holding History

OppenheimerFunds’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$21.9M	Sell	250,445 -30,877	-11%	-$2.81M	0.03%	510
2018 Q4	$28.1M	Buy	281,322 +53,574	+24%	+$5.63M	0.04%	425
2018 Q3	$26.1M	Buy	227,748 +8,758	+4%	+$907K	0.03%	514
2018 Q2	$19.6M	Buy	218,990 +21,138	+11%	+$1.79M	0.02%	582
2018 Q1	$14.5M	Buy	197,852 +186,108	+1,585%	+$12.8M	0.02%	636
2017 Q4	$682K	Sell	11,744 -3,017	-20%	-$159K	﹤0.01%	1358
2017 Q3	$663K	Sell	14,761 -2,310	-14%	-$96K	﹤0.01%	1385
2017 Q2	$674K	Sell	17,071 -976	-5%	-$40.1K	﹤0.01%	1360
2017 Q1	$732K	Buy	18,047 +3,934	+28%	+$154K	﹤0.01%	1316
2016 Q4	$567K	Buy	14,113 +2,461	+21%	+$92.8K	﹤0.01%	1318
2016 Q3	$422K	Sell	11,652 -3,122	-21%	-$107K	﹤0.01%	1340
2016 Q2	$428K	Buy	14,774 +3,341	+29%	+$101K	﹤0.01%	1300
2016 Q1	$400K	Sell	11,433 -3,671	-24%	-$119K	﹤0.01%	1311
2015 Q4	$487K	Buy	+15,104	New	+$490K	﹤0.01%	1294

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

OppenheimerFunds's HAE Position: Q1 2019 in Review

OppenheimerFunds reduced its Haemonetics (HAE) stake by 11% in Q1 2019, selling an estimated $2.81M and leaving 250,445 shares worth $21.9M. The position accounts for 0.03% of the portfolio, ranked #510.

OppenheimerFunds first reported a position in HAE in Q4 2015 and has held it in 14 quarters since. The position peaked at $28.1M in Q4 2018. 260 funds tracked by Wall St. Rank hold HAE as of Q1 2019.

OppenheimerFunds held 250,445 shares of Haemonetics worth $21.9M as of Q1 2019.
OppenheimerFunds sold 30,877 Haemonetics shares in Q1 2019, an estimated $2.81M.
Haemonetics made up 0.03% of OppenheimerFunds's portfolio in Q1 2019, its #510 holding.
OppenheimerFunds first reported a position in Haemonetics in Q4 2015 and has held it in 14 quarters since.
OppenheimerFunds's Haemonetics position peaked at $28.1M in Q4 2018.
260 funds tracked by Wall St. Rank held Haemonetics as of Q1 2019.

Based on OppenheimerFunds's 13F filing for Q1 2019, filed 13 May 2019.